Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov;55(11):2990-2994.
doi: 10.1002/ppul.24945. Epub 2020 Jul 20.

Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

Andrew B Gainey  1 , Anna-Kathryn Burch  2 , Michael J Brownstein  3 , David E Brown  4 , Joseph Fackler  3 , Bri'Anna Horne  3 , Biswajit Biswas  5 , Brittany N Bivens  5 , Francisco Malagon  5 , Robert Daniels  1
Affiliations
Case Reports

Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

Andrew B Gainey et al. Pediatr Pulmonol. 2020 Nov.

Abstract

Cystic fibrosis is associated with significant morbidity and early mortality due to recurrent acute and chronic lung infections. The chronic use of multiple antibiotics without pathogen eradication increases the possibility of extensive drug resistance or even pan-drug resistance (PDR). It is imperative that new or alternative treatment options be explored. We present a clinical case of a 10-year-old female cystic fibrosis patient, infected with a PDR Achromobacter spp. She was treated with cefiderocol, meropenem/vaborbactam, and bacteriophage therapy (Ax2CJ45ϕ2) during two separate admissions in an attempt to clear her infection and restore baseline pulmonary function. The Centers for Disease Control and Prevention confirmed antibiotic susceptibilities, which showed resistance to both cefiderocol and meropenem/vaborbactam. However, after using all three agents concomitantly during the second treatment course, our patient's pulmonary function improved dramatically, and the Achromobacter spp. could not be isolated from sputum samples obtained 8 and 16 weeks after completion of therapy. Overall, the treatment regimen consisting of cefiderocol, meropenem/vaborbactam, and bacteriophage was safe and well-tolerated in our patient.

Keywords: achromobacter; bacteriophage; cefiderocol; cystic fibrosis; meropenem.

PubMed Disclaimer

References

REFERENCES

    1. Wagenlehner F, Naber K. Cefiderocol for treatment of complicated urinary tract infections. Lancet Infect Dis. 2019;19(1):22-23. https://doi.org/10.1016/s1473-3099(18)30722-9
    1. Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA. Activity of cefiderocol and comparators against isolates from cancer patients. Antimicrob Agents Chemother. 2020;64:e01955-19. https://doi.org/10.1128/AAC.01955-19
    1. Nakamuraakamura R, Ito-Horiyama T, Takemura M, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019;63(9):e02031-18. https://doi.org/10.1128/aac.02031-18
    1. Tsuji M, Nakamura R, Kohira N, Ito A, Sato T, Yamano Y S-649266, a novel siderophore cephalosporin: in vitro combination effect of S-649266 and other antibiotics against Gram-negative bacteria. Presentation presented at the: 2016; ECCMID, Amsterdam, The Netherlands.
    1. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016;6:26717. https://doi.org/10.1038/srep26717

Publication types

MeSH terms